Skip to main content

16 publications

Name Date Type Actions

Buyback programs - April 2024

Monthly communication regarding buyback programs

06/05/2024 Liquidity contract

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

29/04/2024 Public releases

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

24/04/2024 Public releases

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

20/03/2024 Public releases

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

24/01/2024 Public releases

Third quarter revenues: €132 million

14/10/2021 Public releases

2021 first half results

2021 Half year results

29/07/2021 Public releases

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

 

05/07/2021 Liquidity contract

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

28/04/2021 Public releases

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

15/04/2021 Public releases